文献速递胸部肿瘤

整合循环肿瘤DNA分析与影像组学用于局限性肺癌的动态风险评估

Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.
PubMed 文献 · Cancer Discov · 2025-01-01

本研究分析418例接受放化疗的非小细胞肺癌患者,开发并验证一种动态风险模型,可在治疗期间准确预测无进展生存。研究优化了血浆无组织变异检测以监测循环肿瘤DNA,并整合影像组学等放化疗前风险因素构建联合模型,改善结局预测;结果提示肿瘤特征、影像组学与放化疗中期循环肿瘤DNA分析具有互补性。

要点

  • 放化疗中期循环肿瘤DNA浓度对疾病进展具有预后价值。
  • 联合肿瘤特征、影像组学与循环肿瘤DNA的模型改善结局预测。
  • 该模型可识别高、低进展风险患者,有望支持反应适应性治疗。

核心结论

  • 肿瘤特征、影像组学与放化疗中期循环肿瘤DNA分析具有互补性,可识别高、低进展风险患者,有望支持反应适应性治疗。

研究设计与样本

  • 分析418例接受放化疗的非小细胞肺癌患者,开发并验证一种动态风险模型。

主要发现

  • 放化疗中期循环肿瘤DNA浓度对疾病进展具有预后价值。
  • 将影像组学等放化疗前风险因素整合入联合模型后,改善结局预测。
  • 优化血浆无组织变异检测并考虑持续性克隆性造血变异对循环肿瘤DNA监测的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. SIGNIFICANCE: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Moding EJ, Shahrokh Esfahani M, Jin C, et al. Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer. Cancer Discov. 2025. PMID: 40299851. doi:10.1158/2159-8290.CD-24-1704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。